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The host factors that promote the survival and persistence of HIV-infected CD4 + T cells are not clear. Kuo et al. demonstrate that the anti-apoptotic protein BIRC5 and its upstream regulator OX40 can promote survival of HIV-1-infected reservoir CD4 + T cells, specifically during clonal proliferation. These findings point to clinical strategies that may reduce persisting viral reservoirs.
SUMMARY
HIV-1 infection of CD4 + T cells leads to cytopathic effects and cell demise, which is counter to the observation that certain HIV-1-infected cells possess a remarkable long-term stability and can persist lifelong in infected individuals treated with suppressive antiretroviral therapy (ART). Using quantitative mass spectrometry-based proteomics, we showed that HIV-1 infection activated cellular survival programs that were governed by BIRC5, a molecular inhibitor of cell apoptosis that is frequently overexpressed in malignant cells. BIRC5 and its upstream regulator OX40 were upregulated in productively and latently infected CD4 + T cells and were functionally involved in maintaining their viability. Moreover, OX40-expressing CD4 + T cells from ART-treated patients were enriched for clonally expanded HIV-1 sequences, and pharmacological inhibition of BIRC5 resulted in a selective decrease of HIV-1-infected cells in vitro. Together, these findings suggest that BIRC5 supports long-term survival of HIV-1-infected cells and may lead to clinical strategies to reduce persisting viral reservoirs. , 2015) , HIV-1 reverse transcripts can be detected through the cytoplasmic microbial DNA sensor IFI16, which results in cellular apoptosis via caspase 1 activation (Monroe et al., 2014) . In activated CD4 + T cells,
HIV-1 induces cell death by causing DNA damage response signals that occur in response to viral integration into host chromosomes and are mediated by DNA-associated protein kinase (DNA-PK) (Cooper et al., 2013) . Moreover, HIV-1 protease can induce cell death by cleaving host procaspase 8 to Casp8p41 (Cummins and Badley, 2015; Sainski et al., 2014) , and HIV-1 Tat can support transcription of pro-apoptotic host cell genes through activation of the transcription factor FOXO3a (Dabrowska et al., 2008) . However, the notion of HIV-1-induced CD4 + T cell death is contradictory to the clinical observation that at least some HIV-1-infected cells have a remarkable ability to survive and persist long term for decades in the presence of highly effective suppressive antiretroviral therapy (Chun et al., 1997; Finzi et al., 1999; Siliciano et al., 2003) . The ability to establish such a highly durable reservoir of virally infected cells suggests that HIV-1 infection may induce specific host pathways that allow infected cells to resist viral cytopathic effects and support long-term survival of virally infected cells. BIRC5, frequently termed ''Survivin,'' is the smallest but arguably the functionally most complex member of the inhibitor of apoptosis protein (IAP) family (Altieri, 2015) . While it is almost ubiquitously expressed in human stem cells during embryogenesis and essential for proper fetal development, its expression in adult tissues is highly restricted (Ambrosini et al., 1997) . The strongest expression in adults is observed in the cytoplasm and nucleus of cancer cells, where it is associated with chemotherapy resistance, increased metastatic activity, and a higher risk for tumor recurrence; for these reasons, it represents one of the biomarkers for malignant disease prognosis most frequently used in clinical practice (Kim et al., 2010; Rö del et al., 2012; Shariat et al., 2009; Xie et al., 2016) . Functionally, BIRC5 can support malignant cell growth by stabilizing the mitotic apparatus, ensuring proper segregation of chromosomes, and maintaining microtubule integrity; this allows for safe and effective completion of cell divisions (Ruchaud et al., 2007) . In addition, BIRC5 has a critical role for protecting cells against intrinsic and extrinsic pathways of apoptosis, most likely through indirect inhibition of caspase 9 activation, while avoiding direct biophysical interactions with apoptosis-promoting molecules (Tamm et al., 1998) .
Besides its critical role as a driver of almost every cancer type in humans, accumulating data suggest a vital function of BIRC5 for regulating viability and proliferation of non-malignant, physiological adult T cells, which are among the few adult human cell populations with detectable levels of BIRC5 expression (Andersson et al., 2015; Croft et al., 2009; Sharief and Semra, 2001) . Within antigen-specific T cells, BIRC5 expression is controlled by OX40 (TNFRSF4, CD134), a member of the TNF receptor superfamily that is expressed on the cell surface and seems to have unique functions for protecting long-term cell viability of memory T cells, particularly at the time of clonal expansion (Song et al., 2005) . For this reason, the OX40-BIRC5 pathway may have a profound influence on shaping and structuring homeostasis and pool sizes of memory T cells and can influence efficient T cell expansion or contraction based on immunological demands.
In the present study, we employed quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics for a detailed analysis of HIV-1-infected CD4 + T cells. Our results showed that cells infected with HIV-1, both during a productive and latent infection state, upregulated BIRC5 and OX40 and were functionally dependent on BIRC5 for maintaining their viability and integrity. Moreover, cells harboring clonally expanded HIV-1 sequences were enriched within OX40-positive CD4 + T cells from ART-treated individuals and could be targeted using pharmaceutical small-molecule antagonists of BIRC5.
RESULTS

Proteomic Profiling Identifies Survival Programs in HIV-1-Infected CD4 + T Cells
Infection with HIV-1 is known to cause profound changes in cellular physiology, but molecular changes occurring in response to viral infection have been difficult to analyze at a protein expression level. Recent technical advances in liquid chromatography-tandem mass spectrometry (LC-MS/MS) enable global, quantitative profiling of changes in the proteome of CD4 + T cells at a high level of molecular resolution and may identify activation of previously unrecognized cellular pathways and programs in HIV-1-infected cells (Greenwood et al., 2016) . To profile changes in the host proteome during viral replication, in vitro activated primary CD4 + T cells from four different HIV-1-negative donors were infected with GFP-encoding R5-tropic HIV-1 in duplicate; 96 hr after infection, GFP + and GFP À CD4 + T cells were sorted and processed for global protein expression profiling by LC-MS/MS using isobaric mass tag labeling with 10-plex tandem mass tag (TMT) reagents for quantification (see also Figure S1A ). This approach identified and quantified 7,761 proteins in GFP + and GFP À CD4 + T cells, of which 552
were differentially expressed between the two cell populations based on robust statistical criteria (FDR-adjusted p < 0.01) ( Figure 1A , see also Table S1 ) and clearly separated the two cell populations in a principal component analysis (see also Figure S1B) . Using established biocomputational algorithms to identify functional pathways in the proteomic signatures in GFP + CD4 + T cells, we noted that the ''cell death and survival''
module accounted for a considerable number of all proteins distinguishing the GFP + and the GFP À CD4 + T cell pools and represented the top functional entity that differentially expressed proteins were enriched for ( Figure 1B) . In contrast to previous findings emphasizing induction of cellular death signals during HIV-1 infection (Cummins and Badley, 2010) , a subsequent computational analysis predicted that GFP + HIV-1-infected CD4 + T cells activated cell survival and viability programs, while protein expression signatures of cell death, apoptosis, and necrosis were mostly de-enriched in this cell population ( Figure 1C ). To explore key molecular factors and pathways regulating the cell survival pathways in HIV-1-infected cells, we entered all differentially expressed proteins predicted to be involved in cell survival pathways (see also Table S2 ) into an in silico functional network linkage (FNL) analysis (Linghu et al., 2013) , which can predict connections between functionally related proteins and detect modules of protein-protein interactions able to drive biological processes. Proteins positioned in the center of network plots and exhibiting the most diverse range of predicted protein-protein connections included BIRC5, a cytoplasmic and nuclear protein and member of the inhibitor of apoptosis protein (IAP) family, and its upstream regulator OX40 located on the cell surface ( Figures 1D and 1E ). Moreover, BIRC5 was among the top effector molecules for the predicted upstream regulators of all differentially expressed proteins ( Figure 1F ). No other members of the IAP family or alternative anti-apoptosis molecules were differentially expressed between GFP + and GFP À CD4 + T cells (see also Figure S1C ). Given the known role of BIRC5 in maintaining cancer cell survival and preserving residual reservoirs of treatment-resistant malignant cells (Altieri, 2015) and the described function of the OX40-BIRC5 pathway in the context of regulating physiological T cell survival, specifically during the vulnerable stage of clonal expansion (Song et al., 2005) , we hypothesized that the OX40-BIRC5 cascade plays a key role in protecting and safeguarding the viability of HIV-1-infected CD4 + T cells. 2D ). An analysis of BIRC5 localization in subcellular compartments by ImageStream flow cytometry indicated that the intracellular increase of BIRC5 in resting CD4 + T cells occurred both in the nucleus and in the cytoplasm, with a tendency for a slightly more profound effect in the nucleus ( Figure 2E ). In addition, using a dual-reporter virus encoding for fluorescent markers allowing us to distinguish CD4 + T cells with productive infection or latent HIV-1 infection , we found that BIRC5 upregulation was detectable in resting CD4 + T cells with either state of infection ( Figures 2F and 2G ). Parallel evaluations of OX40 surface expression largely recapitulated the pattern observed for intracellular BIRC5 expression, with higher levels of OX40 expression being detectable on HIV-1-infected resting CD4 + T cells, in the setting of both productive and latent infection ( Figures 2F and 2H ).
To assess whether BIRC5 can support the ability of HIV-1-infected CD4 + T cells to survive and resist cytopathic effects associated with HIV-1 infection, we took advantage of a previously described in vitro experimental system in which cellular See also Figure S1 and Tables S1 and S2. signs of HIV-1-associated cell death are particularly obvious (Cooper et al., 2013) . Briefly, activated CD4 + T cells were in vitro infected with a VSV-G-pseudotyped, GFP-encoding HIV-1 construct, followed by sorting of GFP + HIV-1-infected CD4 + T cells after 36 hr ( Figure 3A ). As described previously (Cooper et al., 2013) , we observed that a proportion of isolated GFP + CD4 + T cells transition to a GFP-negative phenotype during subsequent in vitro culture ( Figures 3B and 3C) ; this development into a transcriptionally silent HIV-1 infection status is associated with induction of HIV-1-associated cell death in a considerable proportion of cells, while productively infected CD4 + T cells that maintain continuous GFP expression do not show noticeable signs of virally induced cell demise (Figures 3D and 3E; Cooper et al., 2013) . Cells that exhibited signs of early and late apoptosis during transitioning from a GFP-positive to GFP-negative phenotype, as defined based on staining with Annexin V and viability dyes, displayed the lowest intensity of BIRC5 protein expression, while maintenance of cellular integrity and viability in GFP-negative HIV-1-infected CD4 + T cells was associated with enhanced BIRC5 protein expression intensity ( Figure 3F ). Thus, these data suggest that BIRC5 expression can have a functional role in preserving and maintaining cell survival of HIV-1-infected cells, specifically at times when cells transition into a transcriptionally silent (latent) viral infection status.
OX40 Enriches for CD4 + T Cells Encoding for Clonally Expanded HIV-1 Sequences
To determine whether the OX40-BIRC5 pathway maintains survival of HIV-1-infected CD4 + T cells in vivo, we next focused on analyzing cells from HIV-1-infected individuals treated with suppressive antiretroviral therapy who typically maintain small reservoirs of CD4 + T cells that harbor replication-competent HIV-1 (Finzi et al., 1999; Siliciano et al., 2003) . We found that BIRC5 and OX40 displayed higher protein expression intensity in CD4 + T cells expressing PD-1, TIGIT, Lag-3, and the immune activation markers HLA-DR and CD38, surface receptors previously shown to correlate with the size of HIV-1 DNA levels (Figures 4A-4C, see also Figures S2A and S2B; Fromentin et al., 2016; Ruggiero et al., 2015) ; this indicates that OX40 + CD4 + T cells represent distinct cell populations but overlap with cell types previously identified as prime locations for persistence of viral reservoirs. Using fluorescence-activated cell sorting, we isolated OX40 + and OX40 À CD4 + T cells from five study individuals who had received suppressive ART for several years (Figure 4D ). We subsequently subjected DNA from sorted cells to single-template amplification with primers spanning near-fulllength HIV-1, which allowed us to obtain a comprehensive view of proviral cell-associated HIV-1 DNA sequences. Consistent with prior observations (Bruner et al., 2016) , we noted that viral DNA copies with gross deletions or other types of lethal mutations accounted for the vast majority of HIV-1 amplification products ( Figure 4D ). We noted that OX40, known to be associated with long-term survival (Rogers et al., 2001 ) and clonal proliferation (Song et al., 2005) of CD4 + T cells, denoted cells harboring significantly higher frequencies of total HIV-1 DNA copies ( Figure 4E ) and higher numbers of clonally expanded HIV-1 DNA sequences ( Figure 4F ), which may be of particular importance for stabilizing the persistence of viral reservoir cells (see also Table S3 ; Bui et al., 2017; Hosmane et al., 2017; Lee et al., 2017) . Frequencies of intact proviral sequences were also increased in OX40-expressing CD4 + T cells in four of the five patients analyzed (Figures 4G and 4H) . Together, these data show that OX40 + CD4 + T cells are enriched for clonally expanded viral sequences and support the hypothesis that the The availability of small molecule inhibitors of BIRC5 allowed us to assess the functional role of BIRC5 for survival of HIV-1-infected cells and to explore the potential use of BIRC5 inhibitors for therapeutic approaches to reduce persistence of virally infected cells. For this purpose, we focused on YM155, a pharmacological inhibitor of BIRC5 previously tested in human clinical trials in the context of malignant diseases (Clemens et al., 2015) . Using resting CD4 + T cells infected in vitro with a GFP-encoding HIV-1 construct, we observed that co-culture with YM155 led to selective reductions in the frequency of virally infected CD4 + T cells ( Figures 5A-5C) ; this was associated with pronounced increases of apoptosis and cell death markers in GFP + CD4 + T cells but not in GFP À cells ( Figures   5D and 5E ). In this experimental setting, reductions of virally infected CD4 + T cells were noted when YM155 was added to CD4 + T cells prior to infection, immediately after infection or several days after infection, indicating a robust efficacy to selectively induce apoptosis in HIV-1-infected CD4 + T cells (Figure 5E ). To investigate whether YM155 can also influence survival and persistence of latently infected cells, we added See also Figure S2 and Table S3. YM155 to cultures of resting CD4 + T cells infected with the dualreporter virus allowing us to distinguish productively and latently infected CD4 + T cells . We found that addition of YM155 led to substantial reductions of latently and productively infected CD4 + T cells over short and longer durations of co-culture ( Figures 5F and 5G) . Together, these data suggest that both latently and productively infected CD4 + T cells selectively depend on BIRC5 for maintaining cell survival and viability and that pharmacological inhibition of BIRC5 is lethal for many of these cells.
Inhibition of BIRC5 Decreases the Number of In Vivo
HIV-1-Infected CD4 + T Cells
In our next experiments, we evaluated effects of BIRC5 inhibitors on the frequency of in vivo infected CD4 + T cells collected from ART-treated HIV-1 patients. For these experiments, patientderived PBMCs were exposed to YM155 or control DMSO, followed by in vitro culture for defined time periods. Using a ddPCR assay to measure total HIV-1 LTR-gag DNA, we detected a significant reduction of virally infected cells after pharmacological inhibition of BIRC5 ( Figure 6A ). For a more detailed analysis of the changes in viral reservoir cells after inhibition of BIRC5, we performed single-template, near-full-length viral sequencing of cells after co-culture with or without YM155, using CD8
and NK cell-depleted PBMCs of eight randomly selected ART-treated HIV-1-infected patients spanning a spectrum of different viral reservoir sizes ( Figures 6B and 6C ). These experiments showed that relative to control cells, YM155 significantly reduced the frequency of intact HIV-1 sequences ( Figures 6D,  6G , and 6H) and of the total number of HIV-1 sequences ( Figure 6E ). Viral sequences harboring hypermutations, 5-LTR defects, inversions, or gross deletions were also reduced during treatment with YM155, but the degree of susceptibility to YM155 appeared to vary among CD4 + T cells carrying individual types of intact or defective HIV-1 sequences ( Figure 6G ). We also noted that YM155 treatment decreased the number of clonally expanded sequences encoding for identical proviral copies (Figures 6F and 6G, see also Table S4 ). Together, these results suggest that pharmacological targeting of BIRC5 may be able to reduce in vivo infected viral reservoir cells encoding for intact HIV-1 and to decrease the frequency of clonally expanded HIV-1 sequences.
DISCUSSION
Owing to the tremendous progress in antiretroviral drug development, HIV-1 infection is no longer a question of life or death for the vast majority of infected individuals with access to adequate (legend on next page) medical care (Deeks et al., 2013 ). However, on the level of individual viral target cells, it is clear that HIV-1 interferes profoundly with cellular death and survival pathways. Motivated by the decline of CD4 + T cells during untreated HIV-1 infection that is in some cases not fully reversed by antiretroviral therapy, significant advances have been made in understanding mechanisms by which HIV-1 induces target cell death (Doitsh and Greene, 2016) . Nevertheless, it is the ability of certain HIV-1-infected CD4 + T cells to resist such death signals and to survive viral cytopathic effects that transforms HIV-1 infection into a chronic, lifelong illness. In fact, if all HIV-1-infected cells would die as a result of virally induced death programs, HIV-1 would be unable to establish extremely durable viral reservoirs that can persist for decades, despite effective antiretroviral therapy (Badley et al., 2013) . Based on these considerations, we and others (Cummins et al., 2017) hypothesized that HIV-1 can initiate and activate cellular survival programs that may play a critical role for viral long-term persistence and for the inability to cure or eradicate HIV-1 infection. In this work, we showed multiple, complementary pieces of evidence that BIRC5, an anti-apoptosis molecule known for its role in maintaining treatment-resistant reservoirs of cancer cells in the context of malignant diseases, can play a vital role in preserving long-term viability of HIV-1-infected cells. First, a global analysis of protein expression patterns using quantitative mass spectrometry-based proteomics in in vitro infected CD4 + T cells showed activation of cell survival programs that centered around BIRC5 and OX40, its upstream regulator. In addition, we observed upregulation of BIRC5 and OX40 in latently and productively infected resting CD4 + T cells, and higher levels of BIRC5 expression were noted in in vitro infected cells surviving HIV-1-associated death signals occurring during transition from productive to transcriptionally silent HIV-1 infection. Moreover, in cells from ART-treated patients, we noted that OX40 surface expression denoted CD4 + T cells harboring an elevated frequency of intact viral sequences; this is consistent with a role of the OX40-BIRC5 pathway for maintaining and protecting HIV-1-infected cells in vivo. Finally, we found that a pharmaceutical inhibitor of BIRC5 selectively reduced the number of virally infected CD4 + T cells during in vitro culture, including those encoding for intact proviruses; this highlights the functional dependence of HIV-1-infected cells on BIRC5 and opens a perspective for reducing viral reservoir cells in clinical settings. While BIRC5 expression seems restricted to very few cell types in adults, it is clear that expression of this marker represents a mechanism to adapt to and survive during unfavorable or vulnerable conditions (Altieri, 2010) . Although most obviously detected in malignant cells, BIRC5 is also expressed under physiological conditions in CD4 + T cells and seems to have an active role in regulating, protecting, and maintaining memory CD4 + T cell responses. Our data suggest that this physiological mechanism is actively exploited by HIV-1, through an upregulation of BIRC5 in HIV-1-infected cells. Notably, given that we observed overexpression of BIRC5 in both latently and productively infected cells, our data suggest that signals inducing BIRC5 expression are largely independent of the transcriptional state of HIV-1. A cellular damage response, known to occur during viral chromosomal integration (Skalka and Katz, 2005) , may represent a triggering signal, although other molecular signals may be required for a sustained increase of BIRC5 expression. Interestingly, a recent study raised the provocative possibility that the presence of chromosomally integrated HIV-1, even in the absence of detectable viral gene expression, may be sufficient to increase the host cell propensity to undergo DNA damage and promote a durable accumulation of DNA damage response signals (Piekna-Przybylska et al., 2017) ; the upregulation of BIRC5 and OX40 may represent a specific cell-intrinsic immune response to such events. An important question for future studies will be to determine whether BIRC5 upregulation preferentially occurs in specific subsets of infected cells; given that BIRC5 is expressed in several adult human stem cells (Feng et al., 2013; Fukuda et al., 2004) , it may be reasonable to hypothesize that BIRC5-mediated preservation of viral reservoir cells is most active in immature, long-lasting CD4 + T cells that sometimes can imitate stem cell behavior (Buzon et al., 2014; Jaafoura et al., 2014) .
A series of recent studies have highlighted the fact that clonal proliferation of T cell encoding for intact, replication-competent virus represents a driving force for viral reservoir stabilization (Bui et al., 2017; Hosmane et al., 2017; Lee et al., 2017 ). Our See also Table S4. work extends these findings by defining OX40 as a phenotypic marker for CD4 + T cells enriched for clonally expanded HIV-1 sequences. This observation is consistent with the described functional role of the OX40-BIRC5 pathway in protecting and safeguarding T cells during the vulnerable phase of clonal proliferation (Song et al., 2005) and may help to isolate and better characterize clonally expanded HIV-1-infected T cells in future studies. A recent study suggested that expression of CD30 (CD153, TNFRSF8), a member of the TNF surface receptor superfamily closely related to OX40, was also associated with an increased frequency of proviral HIV-1 sequences in CD4 + T cells from ART-treated patients, suggesting that the TNF receptor superfamily may be more universally involved in maintaining viral reservoir cells (Hogan et al., 2018) . Based on observations in animal models, OX40 does not control initial proliferative steps but is responsible for maintaining late, longterm memory T cell survival (Rogers et al., 2001; Xiao et al., 2008) and acts in conjunction with its ligand OX40L expressed on professional antigen-presenting cells (APCs); how these interactions support clonal proliferation of HIV-1-infected T cells is an important area for future studies. Whether OX40 is also expressed on HIV-1-infected CD4 + T cells undergoing clonal proliferation in tissue compartments outside the peripheral blood is currently uncertain, but a recent study suggested OX40 upregulation on enteric HIV-1-infected CD4 + T cells (Yoder et al., 2017) . Results from recent clinical studies have emphasized the high resilience of HIV-1 reservoir cells against eradication efforts. Multiple studies designed to promote viral elimination through disruption of viral latency have failed to induce meaningful reductions of viral reservoir size (Archin et al., 2012; Sø-gaard et al., 2015) , possibly due to the ability of HIV-1-infected cells to survive during pharmacological induction of viral transcription (Shan et al., 2012) or during CD8 T cell-mediated immune recognition (Huang et al., 2018) . Whether BIRC5 contributes to cell survival during viral latency reversal is an interesting question that our work did not address. However, our results suggest that higher levels of BIRC5 expression during productive and latent HIV-1 infection may sensitize HIV-1-infected CD4 + T cells to BIRC5 inhibition, so that pharmacological blockade of BIRC5 may lead to a notable reduction of the viral reservoir, even when not combined with disruption of viral latency. Although the susceptibility to pharmacologic BIRC5 inhibition varied among in vivo HIV-1-infected cells and may possibly be influenced by off-target effects of the YM155 molecule, these data suggest that viral reactivation is not a prerequisite for effective targeting of latently infected cells. Thus, pharmacological inhibition of the BIRC5-OX40 pathway may represent a promising strategy for reducing persisting reservoirs of latently infected cells in clinical settings.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: For flow cytometric analysis, cells were acquired on an LSR Fortessa flow cytometer (Becton Dickinson). Cell sorting was performed by the Ragon Institute Imaging Core Facility, and resulted in isolation of lymphocytes with the defined phenotypic characteristics of > 95% purity. Data were analyzed using FlowJo software (Treestar). For imaging flow cytometry, cells were acquired using the ImageStream X MKII system (Amnis) located in the MGH Department of Pathology Flow and Image Cytometry Core. Images of the cells were analyzed with IDEAS.6 software (Amnis).
Liquid Chromatography-Mass Spectrometry Liquid chromatography-mass spectrometry analyses were performed as previously described in detail (Mertins et al., 2013; Svinkina et al., 2015) . Briefly, 1-2x10 6 sorted CD4 + T cells were pelleted and washed. Cellular proteins were extracted, disulfide bonds reduced and alkylated, and proteins digested with LysC followed by trypsin. The resulting peptides in each sample were subsequently labeled for quantitative analysis with one of the mass tag reagents comprising the 10-plex TMT reagent (Thermo Fisher). This approach enabled simultaneous analysis of 9 samples and a common reference sample constructed of aliquots of all 9 samples, as previously described (Mertins et al., 2016) and shown in Figure S1A . Labeled peptides from all 10 labeled samples were combined and fractionated by basic reversed-phase (bRP) chromatography to decrease sample complexity and increase the dynamic range of detection. The global proteome of each sample was measured with 24 bRP fractions on a Thermo Q Exactive Plus instrument. A normalized collision energy of 31 was used for TMT-samples. MS/MS scans were acquired at a resolution of 35,000. All MS/MS raw data were analyzed using Spectrum Mill Proteomics Workbench (Agilent Technologies) searching against a sequence database containing 59,088 proteins (UniProt human reference proteome including isoforms obtained October 2014, 150 common laboratory contaminants, and 9 HIV-1 sequences (NL4-3 with a Ba-L-derived R5-tropic envelope sequence)). A precursor mass tolerance of 20 ppm and a product ion tolerance of 20 ppm (higher-energy collisional dissociation spectra) were allowed. Tryptic enzyme specificity was required, but configured to allow cleavage of Lys-Pro or Arg-Pro bonds with up to four missed cleavages allowed to account for the Lys-C, trypsin combined digestion. Carbamidomethylation of cysteine and TMT-tags on lysine residues and acetylation of protein N termini were employed as fixed modifications. Deamidation of Asn and oxidation of Met were set as variable modifications. Protein quantification was based on defining ratios of mass-tag reporter ions and rationing the same peptide values across samples and to the common reference as described (Mertins et al., 2016; Mertins et al., 2013) . Settings in Spectrum Mill were adjusted to provide a peptide FDR of 1%-2% and a protein FDR of 0%-1%. Only proteins with > 2 peptides and at least 2 TMT ratios in each replicate were counted as being identified and quantified. Differentially-expressed proteins between GFP + and GFP -CD4 + T cells were analyzed using a moderated F test with the ''lmFit'' function in limma (Ritchie et al., 2015) . Gene ontologies of differentially expressed proteins were identified using Ingenuity Pathway Analysis (IPA, QIAGEN).
HIV-1 LTR-Gag DNA quantification Sorted CD4 + T cell populations were digested with lysis buffer to extract cell lysates, or subjected to DNA extraction using the DNeasy Blood & Tissue kit (QIAGEN). We amplified HIV-1 LTR-Gag DNA using digital droplet PCR (Bio-Rad), with primers and probes described previously (Buzon et al., 2014) (127bp 5 0 LTR-gag amplicon; HXB2 coordinates 684-810). PCR was performed using the following program: 95 C for 10 min, 45 cycles of 94 C for 30 s and 60 C for 1 min, 72 C for 1 min. The droplets were subsequently read by the QX100 droplet reader and data were analyzed using QuantaSoft software (Bio-Rad) (Kiselinova et al., 2016) .
Single-genome, near-full length proviral sequencing Genomic DNA was extracted from indicated cell populations using the QIAGEN DNeasy Blood & Tissue kit (QIAGEN). DNA diluted to single genome levels based on Poisson distribution statistics and ddPCR results was subjected to single-genome amplification using Invitrogen Platinum Taq and nested primers spanning near full-length HIV-1 (HXB2 coordinates 638-9632). Primers were previously published Li et al., 2007) . PCR products were visualized by agarose gel electrophoresis. All sequences were subjected to Illumina MiSeq sequencing with a median of approximately 2500 reads per base. Resulting short reads were de novo assembled and aligned to HXB2 using MUSCLE (Edgar, 2004) to identify internal inversions, large deletions, premature/lethal stop codons, or packaging signal defects. Presence/absence of APOBEC-3G/3F-associated hypermutations was determined using the Los Alamos HIV Sequence Database Hypermut 2.0 program. Viral sequences that lacked all mutations listed above and had < 15 base pairs deletions in the sequenced 5-LTR region were classified as ''intact'' (Bruner et al., 2016) . If a near-full length sequence showed a mapped 5 0 deletion that removes the primer-binding site, but otherwise showed no lethal sequence defects, the missing 5 0 sequence was inferred to be present, and this sequence was considered as an ''inferred intact'' HIV-1 sequence. Phylogenetic distances between sequences were examined using ClustalX-generated neighbor joining algorithms .
Functional assays
To test the influence of BIRC5 inhibition on survival and persistence of HIV-1-infected CD4 + T cells, PBMCs from HIV-1-negative persons were infected with HIV-1 as described above, and incubated in R10 medium supplemented with IL-2 (25 IU/ml) in the presence of YM155 (Selleckchem) at a concentration of 200nM, or DMSO as control; at selected time points, cells were subjected to flow cytometric analysis. For in vivo infected cells derived from ART-treated HIV-1 patients, PBMC were depleted of CD8 and NK cells using immunomagnetic cell separation (autoMACS Pro, Miltenyi) and incubated in IL-2 supplemented R10 medium containing YM155 (200nM) or DMSO. Zidovudine (AZT, obtained from the NIH AIDS reagent repository #3485) was added at a concentration of 400nM to block spreading of autologous virus during in vitro culture. After indicated culture periods, cells were subjected to HIV-1 gag quantification using ddPCR, or processed to cell sorting for isolation of viable cells, determined by Blue viability dye intensity, and subsequent single-genome, near full-length viral sequencing .
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are summarized as individual data plots or pie charts. Differences were tested for statistical significance using a Mann Whitney U test, paired Wilcoxon test, or Friedman test, followed by Dunn's test for multiple comparison where indicated.
DATA AND SOFTWARE AVAILABILITY
Mass spectrometry data were deposited in MassIVE (https://massive.ucsd.edu; accession number MSV000082229).
